Status Unknown
A Pilot Study of 68Ga-FAPI-RGD PETCT Imaging in the Lung Cancer Patients
Led by Peking Union Medical College Hospital · Updated on 2024-07-05
60
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled with short half-life isotopes. Lung cancer tissues express fibroblast activating protein FAP, and also have high expression of integrin αVβ3 receptor on the surface of blood vessels. In this study, a novel dual-target imaging agent 68Ga-FAPI-RGD was used for PET/CT imaging of lung cancer.
CONDITIONS
Brief Title
68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients
Who Can Participate
Eligibility Criteria
Inclusion Criteria:
- patients with confirmed or suspected lung cancer;
- 68Ga-FAPI-RGD and 18F-FDG(or 68Ga-FAPI or 68Ga-RGD) PET/CT within 2 week;
- signed written consent.
Exclusion Criteria:
- pregnancy;
- breastfeeding;
- any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Research Team
Z
Zhaohui Zhu, MD,PHD
R
Rongxi Wang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here